<DOC>
	<DOCNO>NCT01669096</DOCNO>
	<brief_summary>The purpose study assess safety immunogenicity two dos TB vaccine administer accord 0 , 1 month schedule . In , addition , blood sample collect different time point vaccination analyse see exactly gene activate vaccine use assay call mRNA expression profiling . The different method mRNA expression profile use whole blood sample versus Peripheral Blood Mononuclear cell ( ) ( PBMCs ) , also compare .</brief_summary>
	<brief_title>Study Healthy Adults Evaluate Gene Activation After Vaccination With GlaxoSmithKline ( GSK ) Biologicals ' Candidate Tuberculosis ( TB ) Vaccine GSK 692342</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol . A male female , include , 18 50 year age time obtain informed consent . Written inform consent obtain subject . Healthy subject establish medical history clinical examination enter study . Known BCG vaccination presence BCG scar . Seronegative human immunodeficiency virus1 . Female nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day screen day first vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug within six month prior first vaccine dose ( corticosteroid , mean prednisone ≥ 20 mg/day equivalent ) . Inhaled topical steroid allow . Administration longacting immunemodifying drug start 2 year first dose plan administration study . Planned administration/administration vaccine/product foreseen study protocol within period start 30 day first dose study vaccine end last study visit . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product ( pharmaceutical product device ) . History TB disease . History reaction hypersensitivity likely exacerbate component vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . QuantiFERON® TB Gold positive test result . History medically confirm autoimmune disease . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . History reaction hypersensitivity likely exacerbate component vaccine . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>adult</keyword>
	<keyword>healthy</keyword>
	<keyword>Tuberculosis vaccine</keyword>
	<keyword>mRNA expression</keyword>
	<keyword>HIV negative</keyword>
</DOC>